Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 619 results
Found 619 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Wagner GJ, Goggin K, Remien RH, et al. "A closer look at depression and its relationship to HIV antiretroviral adherence." Ann Behav Med. 2011;42(3):352-60.
Gange SJ, Kitahata MM, Saag MS, et al. "Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)." Int J Epidemiol. 2007;36(2):294-301.
Vogler MA, Smeaton LM, Wright RL, et al. "Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227." J. Acquir. Immune Defic. Syndr.. 2014;65(5):542-50.
Luetkemeyer AF, Rosenkranz SL, Lu D, et al. "Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study." Clin. Infect. Dis.. 2015;60(12):1860-3.
Healy B, De Gruttola V, Pagano M. "Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations." Biometrics. 2007;63(3):742-50.
Mugavero MJ, May M, Ribaudo HJ, et al. "Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study." J. Acquir. Immune Defic. Syndr.. 2011;58(3):253-60.
Bartlett JA, Chen S-S, Quinn JB. "Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview." HIV Clin Trials. 2007;8(4):221-6.
Evans SR, Fichtenbaum CJ, Aberg JA. "Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087." HIV Clin Trials. 2007;8(1):45-52.
Thio CL, Smeaton L, Hollabaugh K, et al. "Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks." AIDS. 2015;29(10):1173-82.
Li JZ, Chapman B, Charlebois P, et al. "Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy." PLoS ONE. 2014;9(3):e90485.
Macatangay BJC, Zheng L, Rinaldo CR, et al. "Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181." Clin. Vaccine Immunol.. 2010;17(9):1452-9.
Flexner C, Tierney C, Gross R, et al. "Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial." Clin. Infect. Dis.. 2010;50(7):1041-52.
Alonzo TA, Nakas CT, Yiannoutsos CT, Bucher S. "A comparison of tests for restricted orderings in the three-class case." Stat Med. 2009;28(7):1144-58.
Ofotokun I, Na LH, Landovitz RJ, et al. "Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257." Clin. Infect. Dis.. 2015;60(12):1842-51.
Lalama CM, Jennings C, Johnson VA, et al. "Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity." J. Clin. Microbiol.. 2015;53(8):2659-66.
Ribaudo HJ, Kuritzkes DR, Gulick RM. "A comparison of three initial antiretroviral AIDS regimens." N. Engl. J. Med.. 2007;357(10):1056-7.
Firnhaber C, Smeaton L, Saukila N, et al. "Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas." Int. J. Infect. Dis.. 2010;14(12):e1088-92.
Okusanya O, Forrest A, DiFrancesco R, et al. "Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks." Antimicrob. Agents Chemother.. 2007;51(5):1822-6.
Day JR, Martínez LE, Sásik R, et al. "A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay." J. Virol. Methods. 2006;137(1):125-33.
Shivakoti R, Yang W-T, Gupte N, et al. "Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation." Clin. Infect. Dis.. 2015;61(1):102-10.
Balagopal A, Gupte N, Shivakoti R, et al. "Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort." Open Forum Infect Dis. 2016;3(3):ofw118.
Riddler SA, Aga E, Bosch RJ, et al. "Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy." J. Infect. Dis.. 2016;213(4):556-60.
Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. "Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)." AIDS Res Ther. 2010;7:30.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.
Godfrey C, Villa C, Dawson L, Swindells S, Schouten JT. "Controlling healthcare-associated infections in the international research setting." J. Acquir. Immune Defic. Syndr.. 2013;62(4):e115-8.
Melvin AJ, Kang M, Hitti J, et al. "Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy." Antivir. Ther. (Lond.). 2008;13(3):349-55.
Zhou L, Kitch DW, Evans SR, et al. "Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy." Neurology. 2007;68(24):2113-9.
Carlson JM, Brumme CJ, Martin E, et al. "Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1." J. Virol.. 2012;86(24):13202-16.
Girouard MP, Sax PE, Parker RA, et al. "The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States." Clin. Infect. Dis.. 2016;62(6):784-91.
Morris BL, Scott CA, Wilkin TJ, et al. "Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development." HIV Clin Trials. 2012;13(1):1-10.

Pages